[go: up one dir, main page]

MX2009008877A - Variantes de transglutaminasa con especificidad mejorada. - Google Patents

Variantes de transglutaminasa con especificidad mejorada.

Info

Publication number
MX2009008877A
MX2009008877A MX2009008877A MX2009008877A MX2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A
Authority
MX
Mexico
Prior art keywords
improved specificity
variants
transglutaminase
transglutaminase variants
improved
Prior art date
Application number
MX2009008877A
Other languages
English (en)
Inventor
Jing Su
Sean Hu
Xao Zin
Wang Jianhua
Chihchuan Chang
Leif Noerskov-Lauritsen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/058571 external-priority patent/WO2008020075A1/en
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of MX2009008877A publication Critical patent/MX2009008877A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)

Abstract

Se proporcionan variantes de transglutaminasa de Streptoverticillium ladakanum, variantes las cuales tienen una selectividad mejorada para Gln-141 de la hormona de crecimiento humana.
MX2009008877A 2007-02-22 2008-02-22 Variantes de transglutaminasa con especificidad mejorada. MX2009008877A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07102886 2007-02-22
PCT/EP2007/058571 WO2008020075A1 (en) 2006-08-18 2007-08-17 Transglutaminase variants with improved specificity
PCT/EP2008/052190 WO2008102007A1 (en) 2007-02-22 2008-02-22 Transglutaminase variants with improved specificity

Publications (1)

Publication Number Publication Date
MX2009008877A true MX2009008877A (es) 2009-08-28

Family

ID=39709668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008877A MX2009008877A (es) 2007-02-22 2008-02-22 Variantes de transglutaminasa con especificidad mejorada.

Country Status (11)

Country Link
US (2) US20100099610A1 (es)
EP (2) EP2121744A1 (es)
JP (2) JP2010518843A (es)
KR (1) KR20090123857A (es)
CN (1) CN101679503A (es)
AU (1) AU2008219238A1 (es)
BR (1) BRPI0808014A2 (es)
CA (1) CA2678669A1 (es)
MX (1) MX2009008877A (es)
RU (1) RU2009134725A (es)
WO (2) WO2008102007A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
EP4082564A1 (en) * 2014-06-12 2022-11-02 CSPC Megalith Biopharmaceutical Co., Ltd. Homogenous antibody drug conjugates via enzymatic methods
CN105462950B (zh) * 2016-02-16 2017-09-26 上海青瑞食品科技有限公司 一种液体酶制剂及制备方法
CN109641911B (zh) 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
WO2019057772A1 (en) 2017-09-19 2019-03-28 Paul Scherrer Institut METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE
CN111511389A (zh) * 2017-11-07 2020-08-07 科德克希思公司 转谷氨酰胺酶变体
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
EP3801629A1 (en) 2018-05-29 2021-04-14 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US20220133904A1 (en) 2019-03-19 2022-05-05 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
CN111944778B (zh) * 2020-08-14 2022-06-21 安徽医学高等专科学校 谷氨酰胺转胺酶突变体及其编码基因和应用
EP4213886A1 (en) 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers
CA3196218A1 (en) 2020-10-25 2022-04-28 Philipp SPYCHER Means and methods for producing antibody-linker conjugates
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
US20250282786A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Tricyclic TLR7 Agonists and Uses Thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785276A4 (en) * 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
JPH1175876A (ja) * 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
BR0014059B1 (pt) * 1999-09-30 2013-02-05 processo para produzir transglutaminase.
BR0113304A (pt) * 2000-08-17 2004-01-06 Ajinomoto Kk Método para planejar e preparar uma transglutaminase mutante, mtg mutante transglutaminase mutante, gene, dna recombinante, microorganismos, método para produzir uma mtg mutante ou uma transglutaminase mutante, e, cristais de mtg monoclìnicos
US6660510B2 (en) * 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
WO2003074004A2 (en) * 2002-03-01 2003-09-12 Szu-Yi Chou Method of producing antigens
US7101695B2 (en) * 2002-03-01 2006-09-05 Szu-Yi Chou Method of producing transglutaminase having broad substrate activity
CN1243022C (zh) * 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
EP1708755B1 (en) * 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
EP1893239A2 (en) * 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of growth hormone
WO2007020290A1 (en) * 2005-08-18 2007-02-22 Novo Nordisk Health Care Ag Transglutaminase variants with improved specificity

Also Published As

Publication number Publication date
CA2678669A1 (en) 2008-08-28
JP2010518842A (ja) 2010-06-03
EP2121744A1 (en) 2009-11-25
AU2008219238A1 (en) 2008-08-28
RU2009134725A (ru) 2011-03-27
EP2118132A1 (en) 2009-11-18
US20100087371A1 (en) 2010-04-08
BRPI0808014A2 (pt) 2014-06-17
JP2010518843A (ja) 2010-06-03
WO2008102007A1 (en) 2008-08-28
KR20090123857A (ko) 2009-12-02
CN101679503A (zh) 2010-03-24
US20100099610A1 (en) 2010-04-22
WO2008102008A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MX2009008877A (es) Variantes de transglutaminasa con especificidad mejorada.
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
PH12015501953A1 (en) Substituted nucleotide analogs
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MX2010001073A (es) Metodo para producir una bebida lactea acidificada.
MX2020005214A (es) Formulaciones de anticuerpos.
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2010065815A3 (en) Mini-hepcidin peptides and methods of using thereof
MX2010002974A (es) Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2012002272A (es) Dominios cataliticos de lisil oxidasa y loxl2.
WO2008091908A3 (en) Human cancer stem cells
BRPI0714648B8 (pt) preparação de 3-[(1r,2r)-3-(dimetilamino)-1etil-2-metilpropil] fenol
TW200626171A (en) Fixed dosing of HER antibodies
WO2011005595A3 (en) 2-5a analogs and their methods of use
WO2010003520A3 (en) Anti-tumor immunotherapy
SG2013066634A (en) Enzyme associated with equol synthesis
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009008660A (es) Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
MX2012004404A (es) Caldo de fermentacion de actinomicetos con actividad insecticida.
WO2012064743A3 (en) Methods for improving heart function
WO2013024267A3 (en) Stabilized compositions against ionising radiation
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2009153047A3 (de) Biotechnologische herstellung von acrylsäure
IN2012DN05142A (es)